TLR9 Monotherapy in Immune-Competent Mice Suppresses Orthotopic Prostate Tumor Development

TLR9 Monotherapy in Immune-Competent Mice Suppresses Orthotopic Prostate Tumor Development

Prostate cancer is ranked second in the world for cancer-related deaths in men, highlighting the lack of effective therapies for advanced-stage disease. Toll-like receptors (TLRs) and immunity have a direct role in prostate cancer pathogenesis, but TLR9 has been reported to contribute to both the pr...

Full description

Bibliographic Details
Main Authors: Mark A. Miles, Raymond Luong, Eunice E. To, Jonathan R. Erlich, Stella Liong, Felicia Liong, Jessica M. Logan, John O’Leary, Doug A. Brooks, Stavros Selemidis
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Cells
Subjects:
prostate cancer
toll-like receptor 9
CPG-1668
immunotherapy
Online Access:https://www.mdpi.com/2073-4409/13/1/97

Internet

https://www.mdpi.com/2073-4409/13/1/97

Similar Items